Completed PHASE3 INTERVENTIONAL 1-arm NCT01020448

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer (Triptocare)

Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study

Sponsor: Ipsen

Conditions Prostate Cancer

Interventions Triptorelin (Decapeptyl®)

Updated 7 times since 2017 Last updated: Jan 11, 2019 Started: Nov 30, 2009 Primary completion: Nov 30, 2011 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Ipsen and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ipsen

Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Amstelveen, Netherlands , Amsterdam, Netherlands , Arad, Romania , Avignon, France , Barcelona, Spain , Bilbao, Spain , Bordeaux, France , Bristol, United Kingdom , Brussels, Belgium and 42 more locations